View Archive

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from Eisai Inc.; Exelixis, Inc.; and Merck & Co., Inc.

Renal Cell Carcinoma Playbook for Urologists: Emerging Strategies Across Lines of Therapy to Optimize Patient Outcomes

Renal Cell Carcinoma Playbook for Urologists: Emerging Strategies Across Lines of Therapy to Optimize Patient Outcomes

May 26, 2020

Scientific Session: 8:00 PM – 10:00 PM EDT

Virtual Platform

Renal Cell Carcinoma Playbook for Urologists: Program Overview

Renal cell carcinoma (RCC) remains one of the most difficult solid tumors to treat, but the approach to this disease is rapidly changing. New disease targets, novel single agents, and combination strategies for early-stage and late-stage disease have emerged, and options in the adjuvant setting continue to be explored.

This live webcast features a panel of experts who will address the application of immunotherapy, molecularly targeted agents, and combination regimens for the treatment of RCC. Practical patient case scenarios and panel discussions will highlight the evolving role of adjuvant therapy for locoregional RCC, new paradigms in the frontline management of advanced and metastatic RCC, and multidisciplinary approaches to managing treatment-related adverse events.

Acknowledgement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc.; Exelixis, Inc.; and Merck & Co., Inc.

Target Audience: HCPs Who Treat RCC

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with RCC will be invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explain the biologic rationale for the use of targeted agents and immunotherapies, as single agents and in combination, to treat RCC.
  • Evaluate risk stratification criteria, recent clinical trial data, and how emerging adjuvant strategies may further impact the treatment landscape for RCC.
  • Review practice-changing and emerging data from clinical trials of systemic therapies for the first-line treatment of metastatic RCC.
  • Incorporate knowledge of the safety profiles of systemic therapies with best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC.

Program Chair

Robert A. Figlin, MD., FACP
Robert A. Figlin, MD., FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA


2 Ways to Register
  1. Online: Click here.
  2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701.
Physicians' Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By